Evidence map›Paper›PMID 33194922›Full record

ReviewFrontiers in pediatrics2020

Serum and Urinary N-Terminal Pro-brain Natriuretic Peptides as Biomarkers for Bronchopulmonary Dysplasia of Preterm Neonates.

Zoi Iliodromiti, Evangelos Christou, Nikolaos Vrachnis, Rozeta Sokou, Dionysios Vrachnis, Georgia Mihopoulou, Theodora Boutsikou, Nicoletta Iacovidou

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pediatrics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Zoi IliodromitiNeonatal Department, Aretaieio Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Evangelos ChristouNeonatal Department, Aretaieio Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Nikolaos VrachnisThird Obstetrics and Gynecology Department, Attikon Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Rozeta SokouNICU, "Agios Panteleimon" General Hospital of Nikaia, Piraeus, Greece.
Dionysios VrachnisEndocrinology Unit, Second Obstetrics and Gynecology Department, Aretaieio Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Georgia MihopoulouSecond Obstetrics and Gynecology Department, Aretaieio Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Theodora BoutsikouNeonatal Department, Aretaieio Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
Nicoletta IacovidouNeonatal Department, Aretaieio Hospital, Medical School of National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GRGeneral Hospital of Nikea · GRUniversity General Hospital Attikon · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bronchopulmonary dysplasia (BPD) is a common cause of respiratory illness in preterm newborns with high morbidity and mortality rates. At present, there are no early prognostic biomarkers that can be used in clinical practice to predict the development of BPD. In this review, we critically appraise evidence regarding the use of serum N-terminal pro-brain natriuretic peptide (NTproBNP) levels as a biomarker for BPD in neonates. Furthermore, we summarize studies assessing the feasibility of urinary NTproBNP levels as a non-invasive method to predict BPD in preterm infants. Multiple studies reported a strong association between NTproBNP serum levels and the onset of BPD. For urinary NTproBNP there is scarce evidence showing an association with BPD. Given the promising data obtained by preliminary studies, further assessment of this biomarker in both serum and urine is needed. Standardized reference values should be defined before conducting any further clinical studies.

Indexed as

biomarkerbrainbronchopulmonary dysplasiapreterm neonateserum NTproBNPurinary NTproBNP

Identifiers

PMID33194922
PMCPMC7655774
OpenAlexW3096350958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.